Selegiline
Monoamine Oxidase Inhibitor — NERVOUS SYSTEM
Also known as: (-)-deprenil, (-)-deprenyl, (-)-selegiline, (r)-(-)-deprenyl, (r)-selegiline, anipryl, l-deprenyl, selegiline HCl, selegiline hydrochloride, selegina, selgene, zelapar
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Selegiline is an ofp drug in the Monoamine Oxidase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1989. Its mechanism of action is classified as Monoamine Oxidase Inhibitors and Monoamine Oxidase-B Inhibitors. DrugCentral lists 10 molecular targets, including Maob|Maoa, MAOB and ADRA2B. Recorded indications include Major depressive disorder and Parkinson's disease.
- Approval status: ofp (first approved 1989 by the FDA).
- Drug class: Monoamine Oxidase Inhibitor; Monoamine Oxidase Type B Inhibitor.
- Mechanism of action: Monoamine Oxidase Inhibitors; Monoamine Oxidase-B Inhibitors.
- Molecular targets: Maob|Maoa, MAOB, ADRA2B and SNCA (10 listed in DrugCentral).
- Indications: Major depressive disorder and Parkinson's disease.
- ATC code: N04BD01 (Monoamine oxidase B inhibitors).
- Molecular formula: C13H17N; molecular weight 187.29 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Major depressive disorder
- Parkinson's disease
Contraindications (12)
- Angina pectoris
- Bipolar disorder
- Conduction disorder of the heart
- Disease of liver
- Kidney disease
- Malignant melanoma
- Mania
- Orthostatic hypotension
- Pheochromocytoma
- Psychotic disorder
- Suicidal thoughts
- Tardive dyskinesia
Mechanism & targets
| Mechanism of action (MoA) | Monoamine Oxidase Inhibitors; Monoamine Oxidase-B Inhibitors |
|---|---|
| Established pharmacologic class | Monoamine Oxidase Inhibitor; Monoamine Oxidase Type B Inhibitor |
Molecular targets (10)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Monoamine oxidase | Maob|Maoa | unknown | IC50 7.89 |
| Amine oxidase [flavin-containing] B | MAOB | inhibitor | Ki 7.26 |
| Alpha-2B adrenergic receptor | ADRA2B | unknown | Ki 6.76 |
| Alpha-synuclein | SNCA | unknown | IC50 6.57 |
| Alpha-2A adrenergic receptor | ADRA2A | unknown | Ki 6.17 |
| Amine oxidase [flavin-containing] B | MAOB | unknown | Ki 6.01 |
| Amine oxidase [flavin-containing] B | Maob | unknown | Ki 5.87 |
| Amine oxidase [flavin-containing] A | MAOA | unknown | Ki 5.42 |
| Amine oxidase [flavin-containing] A | MAOA | unknown | Ki 5.04 |
| Amine oxidase [flavin-containing] A | Maoa | unknown | Ki 4.98 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1989-06-05 | FDA | — | SOMERSET | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N04BD01 | NERVOUS SYSTEM › ANTI-PARKINSON DRUGS › DOPAMINERGIC AGENTS › Monoamine oxidase B inhibitors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Hallucination | 335.8 |
| Dyskinesia | 316.7 |
| Parkinsonism hyperpyrexia syndrome | 308.8 |
| Application site rash | 257.2 |
| Application site erythema | 209.4 |
| Hallucination, visual | 190.9 |
| Drug interaction | 134.3 |
| Impulse-control disorder | 129.2 |
| Application site pruritus | 122.6 |
| Application site reaction | 118.4 |
| On and off phenomenon | 117.1 |
| Hypersexuality | 106.3 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Selegiline is on its molecule page.
| Molecular formula | C13H17N |
|---|---|
| Molecular weight | 187.29 g/mol |
| CAS number | 14611-51-9 |
| InChIKey | MEZLKOACVSPNER-GFCCVEGCSA-N |
| PubChem CID | 26757 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Selegiline used for?
DrugCentral lists the following indications for Selegiline: Major depressive disorder and Parkinson's disease.
How does Selegiline work?
Selegiline is classified as Monoamine Oxidase Inhibitors and Monoamine Oxidase-B Inhibitors; its molecular targets in DrugCentral include Maob|Maoa, MAOB (inhibitor), ADRA2B and SNCA.
When was Selegiline first approved?
Selegiline was first approved by the FDA in 1989.
What drug class does Selegiline belong to?
Selegiline is in the Monoamine Oxidase Inhibitor class.
What is the chemical formula of Selegiline?
Selegiline has the molecular formula C13H17N and a molecular weight of 187.29 g/mol.
Browse: all drugs starting with S · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2429 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200904 — compound record and bioactivity
- PubChem CID 26757 — chemical identifiers
- DrugBank DB01037 — drug record
- FDA UNII 2K1V7GP655 — substance identity
- DailyMed: FDA labels for Selegiline — current prescribing information (label search)
- UniProt P27338 (MAOB) — target protein
- UniProt P18089 (ADRA2B) — target protein
- UniProt P37840 (SNCA) — target protein
- UniProt P08913 (ADRA2A) — target protein
- UniProt P21397 (MAOA) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.